Bulletin
Investor Alert

Verve Therapeutics Inc.

NAS: VERV

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 21, 2022, 5:56 p.m.

/zigman2/quotes/227446048/composite

$

32.99

Change

+0.47 +1.45%

Volume

Volume 71,252

Quotes are delayed by 20 min

/zigman2/quotes/227446048/composite

Previous close

$ 33.18

$ 32.52

Change

-0.66 -1.99%

Day low

Day high

$32.37

$35.17

Open

52 week low

52 week high

$29.50

$78.00

Open

Insider Actions for Verve Therapeutics Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/04/2022 Sekar Kathiresan
Chief Executive Officer; Director
1,870   Disposition at $39.9 per share. 74,613
01/04/2022 Sekar Kathiresan
Chief Executive Officer; Director
1,870   Derivative/Non-derivative trans. at $1.39 per share. 2,599
12/28/2021 Sekar Kathiresan
Chief Executive Officer; Director
6,693   Disposition at $39.9 per share. 267,050
12/28/2021 Sekar Kathiresan
Chief Executive Officer; Director
6,693   Derivative/Non-derivative trans. at $1.39 per share. 9,303
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
770   Disposition at $42.21 per share. 32,501
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
4,787   Disposition at $41.24 per share. 197,415
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
36,443   Disposition at $40.02 per share. 1,458,448
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
42,000   Derivative/Non-derivative trans. at $1.39 per share. 58,380
12/23/2021 Sekar Kathiresan
Chief Executive Officer; Director
57,000   Disposition at $39.9 per share. 2,274,300
12/23/2021 Sekar Kathiresan
Chief Executive Officer; Director
57,000   Derivative/Non-derivative trans. at $1.39 per share. 79,230
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
3,269   Disposition at $39.78 per share. 130,040
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
31,139   Disposition at $39.06 per share. 1,216,289
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
16,718   Disposition at $38.31 per share. 640,466
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
5,874   Disposition at $37.38 per share. 219,570
12/22/2021 Andrew Bellinger
Chief Scientific Officer
4,871   Disposition at $39.37 per share. 191,771
12/22/2021 Andrew Bellinger
Chief Scientific Officer
8,161   Disposition at $38.6 per share. 315,014
12/22/2021 Andrew Bellinger
Chief Scientific Officer
1,968   Disposition at $37.42 per share. 73,642
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
57,000   Derivative/Non-derivative trans. at $1.39 per share. 79,230
12/22/2021 Andrew Bellinger
Chief Scientific Officer
15,000   Derivative/Non-derivative trans. at $1.48 per share. 22,200
12/02/2021 Burt A. Adelman
Director
4,700   Acquisition at $31.34 per share. 147,298
12/02/2021 Andrew D. Ashe
See Remarks
4,000   Acquisition at $32.1 per share. 128,400
06/21/2021 GV Management Co. LLC
6,320,905   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
4,029,244   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
4,029,244   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
6,320,905   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
310,285   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
1,007,311   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
620,571   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Redmile Group LLC
886,530   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 ARCH Venture Partners LLC
1,254,405   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 ARCH Venture Partners LLC
1,254,404   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Wellington Management Co. LLP
1,152,490   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Wellington Management Co. LLP
1,343,081   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Rock Springs Capital Management LP
152,926   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Rock Springs Capital Management LP
556,298   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Impresa Management LLC
902,986   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Impresa Management LLC
134,308   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Logos Global Management LP
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Beam Therapeutics, Inc.
270,895   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Cormorant Asset Management LP
709,224   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Novo Holdings A/S (Investment Company)
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
1,100,000   Acquisition at $19 per share. 20,900,000
06/21/2021 Redmile Group LLC
1,050,000   Acquisition at $19 per share. 19,950,000
06/21/2021 Rock Springs Capital Management LP
370,000   Acquisition at $19 per share. 7,030,000
06/21/2021 Logos Global Management LP
370,000   Acquisition at $19 per share. 7,030,000
06/21/2021 Sekar Kathiresan
Chief Executive Officer; Director
2,500   Acquisition at $19 per share. 47,500
06/21/2021 Andrew Bellinger
Chief Scientific Officer
5,000   Acquisition at $19 per share. 95,000
06/21/2021 Margaret Beaudoin
Vice President, Finance
1,000   Acquisition at $19 per share. 19,000
06/21/2021 Cormorant Asset Management LP
275,000   Acquisition at $19 per share. 5,225,000
06/21/2021 Novo Holdings A/S (Investment Company)
350,000   Acquisition at $19 per share. 6,650,000
06/21/2021 The Broad Institute, Inc.
387,830   0

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
8 Purchases
13 Sales
188,263
179,563
Last 6 months
8 Purchases
13 Sales
188,263
179,563
Last 12 months
40 Purchases
13 Sales
37,128,665
179,563

Officers and Executives

Dr. Sekar Kathiresan
Chief Executive Officer & Director
Mr. Andrew D. Ashe
President & Chief Operating Officer
Ms. Allison Dorval
Chief Financial & Accounting Officer
Ms. Margaret Beaudoin
Vice President-Finance
Dr. Andrew Bellinger
Chief Scientific Officer
Mr. Richard Falzone
Vice President-Clinical Operations
Dr. Hari Jayaram
Vice President-Editing & Discovery
Ms. Joan Nickerson
Senior Vice President-Human Resources
Mr. Jason Politi
Senior Vice President-Technical Operations
Dr. Kallanthotatthil Rajeev
Vice President-Chemistry, Manufacturing & Controls
Dr. Ellen Rohde
VP-Preclinical Pharmacology & Toxicology
Mr. John Evans
Director
Ms. Angela Cook
Chief of Staff
Mr. Yasser El-Gamal
Chief Intellectual Property Counsel & VP
Dr. Leslie Stolz
Vice President-Regulatory Affairs
Dr. Burt A. Adelman
Chairman
Ms. Sheila A. Mikhail
Independent Director
Mr. Michael F. MacLean
Independent Director
Dr. Krishna Yeshwant
Independent Director
Link to MarketWatch's Slice.